Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
84 hedge funds and large institutions have $398M invested in Esperion Therapeutics in 2014 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 28 increasing their positions, 12 reducing their positions, and 3 closing their positions.
1,167% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 3
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
193% more capital invested
Capital invested by funds: $136M → $398M (+$262M)
133% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 12
68% more funds holding
Funds holding: 50 → 84 (+34)
60% more call options, than puts
Call options by funds: $3.65M | Put options by funds: $2.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$40.3M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
+$16.2M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$14.7M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$12.8M |
| 5 |
PA
Perceptive Advisors
New York
|
+$9.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$4.02M |
| 2 |
Millennium Management
New York
|
-$2.03M |
| 3 |
Morgan Stanley
New York
|
-$1.32M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.07M |
| 5 |
Jane Street
New York
|
-$1,000K |
ESPR Hedge Fund Activity: Q4 2014 in Review
84 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2014, worth a combined $398M — up 193% from $136M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ESPR positions and 3 closed out — a net gain of 35 holders — while 28 added to existing stakes and 12 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $40.3M. The largest seller was BlackRock Fund Advisors, cutting an estimated $4.02M.
- 84 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2014, up from 50 in Q3 2014.
- Funds reported $398M of Esperion Therapeutics stock for Q4 2014, up 193% quarter-over-quarter.
- 38 funds opened new Esperion Therapeutics positions in Q4 2014 and 3 closed out, a net change of +35 holders.
- The largest Esperion Therapeutics buyer in Q4 2014 was Fidelity Investments, an estimated $40.3M added.
- The largest Esperion Therapeutics seller in Q4 2014 was BlackRock Fund Advisors, an estimated $4.02M sold.
Based on aggregated 13F filings for Q4 2014.